defencath

Generic: taurolidine and heparin

defencath: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
CorMedix Inc. (CRMD)Phase 4

FDA Decisions

Approval1 INDICATIONS AND USAGE LIMITED POPULATION: DEFENCATH ® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients [see Clinical Studies (14) ]. Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult pati(CRMD)

Frequently asked questions

Who is developing defencath?

defencath is being developed by CorMedix Inc..

What is defencath's latest FDA decision?

The most recent tracked FDA decision for defencath is Approval for 1 INDICATIONS AND USAGE LIMITED POPULATION: DEFENCATH ® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients [see Clinical Studies (14) ]. Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult pati, dated November 15, 2023.

Get deeper analysis on defencath

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    defencath — Drug Pipeline, Trials & FDA Status | BioSniper